Current breast cancer risks of hormone replacement therapy in postmenopausal women

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 18, 2006, Pages 2455-2463

  Shah, Nirav R ^a   Wong, Tanping ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen; Hormone replacement therapy; Progestin

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CONJUGATED ESTROGEN; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NANDROLONE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PLACEBO;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CANCER RISK; CARCINOGENICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; ESTROGEN THERAPY; FEMALE; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; META ANALYSIS; PATIENT COMPLIANCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR PROMOTION;

AGE FACTORS; BREAST NEOPLASMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; POSTMENOPAUSE; RISK FACTORS; TIME FACTORS;

EID: 33845577762     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.18.2455     Document Type: Review

References (70)

1. GRADY D: Postmenopausal hormones - therapy for symptoms only. N. Engl. J. Med. (2003) 348(19):1835-1837.
2. MACLENNAN A, LESTER S, MOORE V: Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric (2001) 4(1):58-74.
3. MACLENNAN AH, BROADBENTJL, LESTER S, MOORE V: Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst. Rev. (2004) 4:CD002978.
4. SKOUBY SO, AL-AZZAWI F, BARLOW D et al.: Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas (2005) 51(1):8-14.
5. HICKEY M, DAVIS SR, STURDEE DW: Treatment of menopausal symptoms: what shall we do now? Lancet (2005) 366(9483):409-421.
6. KRONENBERG F: Hot flashes: epidemiology and physiology Ann. NY Acad. Sci. (1990) 592:52-86; discussion 123-133.
7. SCHNEIDER H: General aspects of world-wide HRT. In: Hormone replacement therapy and osteoporosis. Kato J, Minaguchi H, Nishino Y (Eds), Springer, Berlin/New York (2000):1-28.
8. DIETEL M, LEWIS MA, SHAPIRO S: Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum. Reprod. (2005) 20(8):2052-2060.
9. CLEMONS M, GOSS P: Estrogen and the risk of breast cancer. N. Engl. J. Med. (2001) 344(4):276-285.
10. MAGNUSSON C, BARON JA, CORREIA N et al.: Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int. J. Cancer (1999) 81(3):339-344.
11. OLSSON HL, INGVAR C, BLADSTROM A: Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer (2003) 97(6):1387-1392.
12. COLLABORATIVE GROUP ON HORMONAL FACTORS IN BREAST CANCER: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet (1997) 350(9084):1047-1059.
13. KUHL H: Breast cancer risk in the WHI study: the problem of obesity. Maturitas (2005) 51(1):83-97.
14. BERAL V, MILLION WOMEN STUDY C: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (2003) 362(9382):419-427.
15. SCHAIRER C, LUBIN J, TROISI R et al.: Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA (2000) 283(4):485-491.
16. LA VECCHIA C: Estrogen and combined estrogen-progestogen therapy in the menopause and breast cancer. Breast (2004) 13(6):515-518.
17. ROSS RK, PAGANINI-HILL A, WAN PC, PIKE MC: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl. Cancer Inst. (2000) 92(4):328-332.
18. ROSENBERG L, PALMER JR, WISE LA, ADAMS-CAMPBELL LL: A prospective study of female hormone use and breast cancer among black women. Arch. Intern. Med. (2006) 166(7):760-765.
19. KEY T, APPLEBY P, BARNES I, REEVES G, ENDOGENOUS HORMONES AND BREAST CANCER COLLABORATIVE G: Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst. (2002) 94(8):606-616.
20. BERNSTEIN L, ROSS RK: Endogenous hormones and breast cancer risk. Epidemiol. Rev. (1993) 15(1):48-65.
21. BARRETT-CONNOR E, MOSCA L, COLLINS P et al.: Effects of raloxifene on cardiovascular events and breast cancer to postmenopausal women. N. Engl. J. Med. (2006) 355(2):125-137.
22. LIEHR JG: Is estradiol a genotoxic mutagenic carcinogen? Endocr. Rev. (2000) 21(1):40-54.
23. KENEMANS P, BOSMAN A: Breast cancer and post-menopausal hormone therapy. Best Pract. Res. Clin. Endocrinol. Metabol. (2003) 17(1):123-137.
24. LIPPERT C, SEEGER H, MUECK AO: The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Sci. (2003) 72(8):877-883.
25. KENEMANS P: Postmenopausal hormone therapy and breast cancer: what is the problem? Maturitas (2005) 51(1):75-82.
26. CREASMAN WT: Breast cancer: the role of hormone therapy. Semin. Reprod. Med. (2005) 23(2):167-171.
27. LEE SA, ROSS RK, PIKE MC: An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br. J. Cancer (2005) 92(11):2049-2058.
28. CAMPAGNOLI C, CLAVEL-CHAPELON F, KAAKS R, PERIS C, BERRINO F: Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J. Steroid Biochem. Mol. Biol. (2005) 96(2):95-108.
29. DOREN M, REUTHER G, MINNE HW, SCHNEIDER HP: Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. Am. J. Obstet. Gynecol. (1995) 173(5)1446-1451.
30. MCCARTY MF: Androgenic progestins amplify the breast cancer risk associated with hormone replacement therapy by boosting IGF-I activity. Med. Hypotheses (2001) 56(2):213-216.
31. FOURNIER A, BERRINO F, RIBOLI E, AVENEL V, CLAVEL-CHAPELON F: Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int. J. Cancer (2005) 114(3):448-454.
32. MODENA MG, SISMONDI P, MUECK AO et al.: New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas (2005) 52(1):1-10.
33. PIKE MC, SPICER DV, DAHMOUSH L, PRESS MF: Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. (1993) 15(1):17-35.
34. PASQUALINI JR, PARIS J, SITRUK-WARE R, CHETRITE G, BOTELLA J: Progestins and breast cancer. J. Steroid Biochem. Mol. Biol. (1998) 65(1-6):225-235.
35. SPICER DV, PIKE MC: The prevention of breast cancer through reduced ovarian steroid exposure. Acta Oncol. (1992) 31(2):167-174.
36. WYSOWSKI DK, GOLDEN L, BURKE L: Use of menopausal estrogens and medroxyprogesterone in the United States, 1982 - 1992. Obstet. Gynecol. (1995) 85(1):6-10.
37. COLDITZ GA: Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin. Cancer Res. (2005) 11(2 Pt 2):909s-917s.
38. TSAO A: Hormone replacement: no simple answers. In: Business Week Online (2003).
39. ROSSOUW JE, ANDERSON GL, PRENTICE RL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 288(3):321-333.
40. HULLEY S, GRADY D, BUSH T et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA (1998) 280(7):605-613.
41. HERSH AL, STEFANICK ML, STAFFORD RS: National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 291(1):47-53.
42. COLDITZ GA, HANKINSON SE, HUNTER DJ et al.: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. (1995) 332(24):1589-1593.
43. SHAH NR, BORENSTEIN J, DUBOIS RW: Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause (2005) 12(6):668-678.
44. CHLEBOWSKI RT, HENDRIX SL, LANGER RD et al.: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 289(24):3243-3253.
45. ANDERSON GL, CHLEBOWSKI RT, ROSSOUW JE et al.: Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas (2006) 55(2):103-115.
46. BERAL V, BANKS E, REEVES G: Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet (2002) 360(9337):942-944.
47. CHEN C-L, WEISS NS, NEWCOMB P, BARLOW W, WHITE E: Hormone replacement therapy in relation to breast cancer. JAMA (2002) 287(6):734-741.
48. LI CI, MALONE KE. PORTER PL et al.: Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA (2003) 289(24):3254-3263.
49. COLDITZ GA, STAMPFER MJ, WILLETT WC et al.: Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA (1990) 264(20):2648-2653.
50. PORCH JV, LEE IM, COOK NR, REXRODE KM, BURIN JE: Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control (2002) 13(9):847-854.
51. ANDERSON GL. LIMACHER M, ASSAF AR et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 291(14):1701-1712.
52. STEFANICK ML, ANDERSON GL, MARGOLIS KL et al.: Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 295(14):1647-1657.
53. US PREVENTIVE SERVICES TASK FORCE: Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the US Preventive Services Task Force. Ann. Intern. Med. (2005) 142(10):855-860.
54. HULLEY S, FURBERG C, BARRETT-CONNOR E et al.: Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). JAMA (2002) 288(1):58-66.
55. STEINBERG KK, THACKER SB, SMITH SJ et al.: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA (1991) 265(15):1985-1990.
56. NAFTOLIN F, TAYLOR HS, KARAS R et al.: The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil. Steril. (2004) 81(6):1498-1501.
57. LOBO RA: Appropriate use of hormones should alleviate concerns of cardiovascular and breast cancer risk. Maturitas (2005) 51(1):98-109.
58. CRANDALL C: Low-dose estrogen therapy for menopausal women: a review of efficacy and safety. J. Women's Health (2003) 12(8):723-747.
59. KEY J, HODGSON S, OMAR RZ et al.: Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. Cancer Causes Control (2006) 17(6):759-770.
60. ANTONIOU A, PHAROAH PD, NAROD S et al.: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. (2003) 72(5):1117-1130.
61. CHEN WY, MANSON JE, HANKINSON SE et al.: Unopposed estrogen therapy and the risk of invasive breast cancer. Arch. Intern. Med. (2006) 166(9):1027-1032.
62. MILLS PK, BEESON WL, PHILLIPS RL, FRASER GE: Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. Cancer (1989) 64(3):591-597.
63. FOLSOM AR, MINK PJ, SELLERS TA et al.: Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am. J. Public Health (1995) 85(8 Pt 1):1128-1132.
64. STANFORD JL, WEISS NS, VOIGT LF et al.: Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA (1995) 274(2):137-142.
65. HENRICH JB, KORNGUTH PJ, VISCOLI CM, HORWITZ RI: Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J. Clin. Epidemiol. (1998) 51(12):1277-1283.
66. LUCAS FL, CAULEY JA, STONE RA et al.: Bone mineral density and risk of breast cancer: differences by family history of breast cancer. Study of Osteoporotic Fractures Research Group. Am. J. Epidemiol. (1998) 148(1):22-29.
67. SOURANDER L, RAJALA T, RAIHA I et al.: Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet (1998) 352(9145):1965-1969.
68. NEWCOMB PA, TITUS-ERNSTOFF L, EGAN KM et al.: Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol. Biomarkers Prev. (2002) 11(7):593-600.
69. WEISS LK, BURKMAN RT, CUSHING-HAUGEN KL et al.: Hormone replacement therapy regimens and breast cancer risk(1). Obstet. Gynecol. (2002) 100(6):1148-1158.
70. LI CI, ANDERSON BO, DALING JR, MOE RE: Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA (2003) 289(11):1421-1424.